Suppr超能文献

原发性人类非小细胞肺癌中表皮生长因子受体的特征分析

Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer.

作者信息

Veale D, Kerr N, Gibson G J, Harris A L

机构信息

Department of Respiratory Medicine, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

出版信息

Cancer Res. 1989 Mar 1;49(5):1313-7.

PMID:2537147
Abstract

Membrane preparations from 36 human non-small cell lung cancers were examined for the expression of epidermal growth factor (EGF) receptors, and comparisons were made between tumor types and stage. Eight normal lung membrane preparations were also examined. The concentrations of EGF receptors were assessed by ligand binding studies using 125I-radiolabeled EGF. In two point saturation experiments using 0.3 nM 125I-EGF incubated with membranes from 35 primary lung tumors, a median of 18 fmol/mg of protein (range, 1.1 to 530) was found. This was significantly greater than binding to eight lung membranes: median, 6.1 fmol/mg of protein (range, 1.0 to 14.5) (P less than 0.02). Scatchard binding curves obtained in 21 of the 36 tumors and seven of eight of the normal lung preparations showed high and low affinity sites for EGF receptors on all but two tumor membranes. The dissociation constant of the high affinity sites was similar on tumor and normal lung membranes: range, 0.75 to 30 x 10(-10) M/liter. However, the tumors had a significantly higher concentration of these receptor sites: median, 30.4 fmol/mg of protein versus a median of 6.2 fmol/mg of protein on normal lung membranes (P less than 0.01). Likewise, there were significantly more low affinity sites on tumors: median, 237 fmol/mg compared to 60.2 fmol/mg on normal lung (P less than 0.01). No differences were found in this analysis between tumors of different histological subtypes or clinical stage. It is possible that the high level of expression of high affinity sites on lung tumors could be used as a target for ligand-complexed drugs.

摘要

检测了36例人类非小细胞肺癌的膜制剂中表皮生长因子(EGF)受体的表达情况,并对肿瘤类型和分期进行了比较。还检测了8份正常肺膜制剂。通过使用125I放射性标记的EGF进行配体结合研究来评估EGF受体的浓度。在使用0.3 nM 125I-EGF与35例原发性肺肿瘤的膜进行的两点饱和实验中,发现每毫克蛋白质的中位数为18 fmol(范围为1.1至530)。这显著高于与8份肺膜的结合:中位数为每毫克蛋白质6.1 fmol(范围为1.0至14.5)(P小于0.02)。在36例肿瘤中的21例以及8份正常肺制剂中的7份中获得的Scatchard结合曲线显示,除两份肿瘤膜外,所有肿瘤膜上的EGF受体均存在高亲和力和低亲和力位点。肿瘤膜和正常肺膜上高亲和力位点的解离常数相似:范围为0.75至30×10⁻¹⁰ M/升。然而,肿瘤中这些受体位点的浓度显著更高:中位数为每毫克蛋白质30.4 fmol,而正常肺膜上的中位数为每毫克蛋白质6.2 fmol(P小于0.01)。同样,肿瘤上的低亲和力位点也显著更多:中位数为237 fmol/mg,而正常肺上为60.2 fmol/mg(P小于0.01)。在该分析中,不同组织学亚型或临床分期的肿瘤之间未发现差异。肺肿瘤上高亲和力位点的高表达水平有可能被用作配体复合药物的靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验